Use of Meropenem by Continuous Infusion to Treat a Patient with a Bla kpc-2 -Positive Klebsiella pneumoniae Blood Stream Infection

Abstract

Background:

Gram-negative bacterial resistance to antibiotics is of increasing concern. Carbapenem resistance among strains of Klebsiella pneumoniae is a relatively new phenomenon. Resistance attributable to production of carbapenemases is notoriously difficult to combat.

Methods:

Case report and review of the pertinent English-language literature.

Results:

A patient, hospitalized for aortic dissection complicated by intra-abdominal catastrophe and acute kidney injury, developed bacteremia exhibiting meropenem non-susceptibility secondary to expression of bla_KPC-2. High-dose, continuous-infusion meropenem achieved serum drug concentrations above the minimum inhibitory concentration and eradicated the infection.

Conclusion:

This is the first report of a meropenem-non-susceptible carbapenamase-positive Klebsiella pneumoniae blood stream infection treated successfully with high-dose, continuous-infusion meropenem. Application of this regimen in certain patients, such as those with mild-to-moderate renal insufficiency, may be a reasonable option for multi-drug-resistant nosocomial infections.

Get full access to this article

View all access options for this article.

References

Gaynes

, Edwards

, Weinstein

. Overview of nosocomial infections caused by gram-negative bacilli. Clin Infect Dis, 2005; 41:848–854.

Yigit

, Queenan

, Anderson

et al. Novel carbapenem-hydrolyzing beta-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae. Antimicrob Agents Chemother, 2001; 45:1151–1161.

Borer

, Saidel-Odes

, Riesenberg

et al. Attributable mortality rate for carbapenem-resistant Klebsiella pneumoniae bacteremia. Infect Control Hosp Epidemiol, 2009; 30:972–976.

Drusano

. Pharmacodynamics: Critical interactions of ‘bug and drug.’ Nat Rev Microbiol, 2004; 2:289–300.

Elkhaili

, Niedergang

, Pompei

et al. High-performance liquid chromatographic assay for meropenem in serum. J Chromatog B: Biomed Sci Applic, 1996; 686:19–26.

Krueger

, Schroeder

, Hutchison

et al. Pharmacokinetics of meropenem in critically ill patients with acute renal failure treated by continuous hemodiafiltration. Antimicrob Agents Chemother, 1998; 42:2421–2424.

Hermsen

, Maiefski

, Florescu

et al. Comparison of the Modification of Diet in Renal Disease and Cockcroft–Gault equations for dosing antimicrobials. Pharmacother, 2009; 29:649–655.

Brun-Buisson

, Legrand

, Philippon

et al. Transferable enzymatic resistance to third-generation cephalosporins during nosocomial outbreak of multiresistant Klebsiella pneumoniae. Lancet, 1987; 2:302–306.

Nordmann

, Cuzon

, Naas

. The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. Lancet Infect Dis, 2009; 9:228–236.

10.

Roberts

, Kirkpatrick

, Roberts

et al. Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: Intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution. J Antimicrob Chemother, 2009 Jul 64:142–150.

11.

Lorente

, Lorenzo

, Martin

et al. Meropenem by continuous versus intermittent infusion in ventilator-associated pneumonia due to gram-negative bacilli. Ann Pharmacother, 2006; 40:219–223.

12.

Roberts

, Webb

, Paterson

et al. A systematic review on clinical benefits of continuous administration of beta-lactam antibiotics. Crit Care Med, 2009; 37:2071–2078.